XOMA Corporation (NASDAQ:XOMA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “

XOMA has been the subject of several other research reports. ValuEngine raised XOMA Corporation from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 12th. Wedbush reaffirmed a “hold” rating on shares of XOMA Corporation in a research note on Monday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of XOMA Corporation in a research note on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $27.33.

TRADEMARK VIOLATION WARNING: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/02/xoma-corporation-xoma-rating-lowered-to-hold-at-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XOMA. Geode Capital Management LLC grew its stake in XOMA Corporation by 1.3% in the first quarter. Geode Capital Management LLC now owns 600,488 shares of the biotechnology company’s stock valued at $464,000 after acquiring an additional 7,576 shares during the period. California Public Employees Retirement System grew its stake in XOMA Corporation by 95.5% in the first quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 10,640 shares during the period. Wedbush Securities Inc. grew its stake in XOMA Corporation by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 15,827 shares during the period. WFG Advisors LP acquired a new stake in XOMA Corporation in the fourth quarter valued at approximately $1,202,000. Finally, Stonepine Capital Management LLC acquired a new stake in XOMA Corporation in the first quarter valued at approximately $625,000. 32.92% of the stock is owned by institutional investors and hedge funds.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Get a free copy of the Zacks research report on XOMA Corporation (XOMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.